 "ICMR has collected over Rs 171 crore as royalty from Covaxin's sales: Govt")
The Indian Council of Medical Research (ICMR) has received a royalty of Rs 171.74 crore till January 31 from Bharat Biotech from sales of Covaxin, Rajya Sabha was told Tuesday.
The ICMR has spent around Rs 35 crore in research and development of covid vaccine Covaxin.
Funds with ICMR are utilized for health research activities including emerging research priorities and research capacity building, Minister of State for Health Bharati Pravin Pawar said in a written reply.
She was responding to a question on the total money collected by ICMR as royalty from sales of Bharat Biotech's Covaxin and how much of the initial cost of ICMR in doing R and D for the development of Covaxin has been recovered from the amount collected so far.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app